{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck","slug":"asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck","published_at":"2026-06-03T09:48:40+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/e3728c4669a6be447b94641b604fc8e84151e6abd0ff09a122ff3a47a9a90a7a/eyJlcGlzb2RlSWQiOiJhYTYwYjA1Zi02MGM2LTQ2MTYtOWRmOS03YTk3Yzc1MzU5ZDUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExZmY4N2VmYjViMGJhZGIzMTNmMjJhL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTNfXzExLTQ4LTQ2Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/e3728c4669a6be447b94641b604fc8e84151e6abd0ff09a122ff3a47a9a90a7a/eyJlcGlzb2RlSWQiOiJhYTYwYjA1Zi02MGM2LTQ2MTYtOWRmOS03YTk3Yzc1MzU5ZDUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExZmY4N2VmYjViMGJhZGIzMTNmMjJhL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTNfXzExLTQ4LTQ2Lm1wMyJ9.mp3","summary":"At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show . For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population . Immuneering , BMS/BioNTech , Merck , Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China’s Innovent Biologics as it seeks to bolster its oncology pipeline . Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.","meta_description":"At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Sum…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1624,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}